Fig. 2From: Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort studyChanges in FVC and DLCO according to the autoantibody status. a No difference in the change in FVC between the autoantibody-negative and autoantibody-positive groups (p = 0.168); b No difference in the change in DLCO between the autoantibody-negative and autoantibody-positive groups (p = 0.356). DLCO, diffusing capacity of the lungs for carbon monoxide; FVC forced vital capacityBack to article page